|
|
News Breaks | | | | March 13, 2013 | | 08:03 EDT |  | ISIS | Isis Pharmaceuticals announces positive clinical data from ISIS-CRPRx
Isis Pharmaceuticals announced that ISIS-CRPRx selectively reduced severe elevations in C-reactive protein in humans. Data from a Phase 1 clinical study showed that ISIS-CRPRx produced statistically significant, dose-dependent reductions in CRP response following an endotoxin challenge, which produces immune responses similar to those seen with bacterial infections. In this study, significant reduction of the endotoxin-induced CRP response was achieved in the healthy volunteers treated with ISIS-CRPRx, with no changes in other important immune modulators, such as TNF-alpha, IL-6, and other cytokines and chemokines. Selective reduction of CRP could offer a safer approach to treating patients who have chronic inflammatory diseases, such as rheumatoid arthritis, by potentially lowering the risk of infections, a common side effect of other anti-inflammatory drugs, such as TNF-alpha inhibitors. A Phase 2 study of ISIS-CRPRx in patients with rheumatoid arthritis is currently underway with data anticipated in the middle of this year. | |
|
News For ISIS From The Last 14 Days Check below for free stories on ISIS the last two weeks. |
|
|
| May 20, 2013 | | 07:34 EDT |  | ISIS | UBS to host a conference
 Subscribe for More Information | | | May 9, 2013 | | 16:59 EDT | | ISIS | Isis Pharmaceuticals earns $3.5M from Biogen
Subscribe for More Information | | | 11:15 EDT |  | ISIS | High option volume stocks: BKS ISIS BRY GMCR JOE
| | | 06:16 EDT |  | ISIS | Isis Pharmaceuticals 9M share Secondary priced at $19.00
Subscribe for More Information | |
|
|
|
|
|
|
